NCT04928677
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: GPC3
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 1 Year to 21 Years (Child, Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for part A of the study
Exclusions: Patients over the age of 21; Patients with CNS metastasis
https://ClinicalTrials.gov/show/NCT04928677